Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q2 2025 Earnings Presentation

14 slides from Day One Biopharmaceuticals's earnings presentation, Aug 5, 2025

  1. Slide 1: Second Quarter 2025 Financial Results & Corporate Progress

    AUGUST 2025 Second Quarter 2025 Financial Results & Corporate Progress

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc

  3. Slide 3: Agenda & Day One Participants

    Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM Launch Performance Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All, joined by: Mike Vasconcelles (Head of R&D)

  4. Slide 4: Opening Remarks

    Opening Remarks Jeremy Bender Chief Executive Officer

  5. Slide 5: Second Quarter 2025 Highlights

    EMA: European Medicines Agency 1 Regulatory submission process executed by Ipsen 2 Represents cash, cash equivalents and short-term investments as of June 30, 2025. Net revenue for the most recent 12 months represents results for the 12-month period ended June 30, 2025. Second Quarter 2025 Highlight

  6. Slide 6: OJEMDA Launch Performance

    OJEMDA Launch Performance Lauren Merendino Chief Commercial Officer

  7. Slide 7: Commercial Performance by the Numbers

    Commercial Performance by the Numbers $33.6M Q2 2025 OJEMDA Net Product Revenue 1,062 1 Prescriptions are approximations based on data available as of June 30, 2025. 2 Second quarter 2024 reflects a partial quarter following OJEMDA receiving U.S. FDA accelerated approval for relapsed or refractory B

  8. Slide 8: One Year In: OJEMDA Delivering Steady Revenue Growth

    1 Q3 2024 and Q4 2024 revenue included approximately $1.6M and $1.4M, respectively of revenue associated with Ex-US sales which has been removed for the purposes of calculating compounded quarterly revenue growth rate. 2 Compounded quarterly growth represents the comparison of Q3 2024 to Q2 2025. Ne

  9. Slide 9: One Year In: Consistent Uptake Driving Quarterly OJEMDA Growth

    Prescriptions For The Most Recent 12 Months OJEMDA Prescriptions (TRx)1 +15% One Year In: Consistent Uptake Driving Quarterly OJEMDA Growth Achieved greater than 1,000 scripts in Q2 2025 Prescription Highlights Strong and consistent patient demand, driven by new patient starts and high percentage of

  10. Slide 10: Expanding Prescriber Adoption with Meaningful Growth Opportunity Remaining

    Expanding Prescriber Adoption with Meaningful Growth Opportunity Remaining Launch Dec 2024 Jun 2025 1 Patient 2-3 Patients 4-5 Patients Growing Depth of Prescribing by Account Since Launch 6+ Patients Continued growth in breadth of unique prescribers initiating at least one patient on OJEMDA Growth

  11. Slide 11: OJEMDA Priorities to Drive Revenue Growth in 2025

    OJEMDA Priorities to Drive Revenue Growth in 2025 r/r, relapsed or refractory. Drive depth of prescribing with current prescribers Encourage non-user HCPs to try OJEMDA in their next r/r pLGG patient Establish OJEMDA as standard of care in 2nd line r/r BRAF-altered pLGG Support prescribers and patie

  12. Slide 12: Financial Performance

    Financial Performance Charles York Chief Operating Officer & Chief Financial Officer

  13. Slide 13: Second Quarter 2025 Financial Results

    All financial information as of 6/30/25 is unaudited. 1 Includes stock-based compensation expense of $3.6 million and $7.8 million for the three and six months ended 6/30/25, and $4.7 million and $9.4 million for the three and six months ended 6/30/24. 2 Includes stock-based compensation expense of

  14. Slide 14: Thank You

    Thank You

Day One Biopharmaceuticals — Q2 2025 Earnings Presentation on 6ix